Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + nivolumab versus nivolumab alone after complete resection of stage III-IV melanoma
MOH_2021-08-12_010203Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Relatlimab + nivolumab FDC with Nivolumab monotherapy (2 arms). Primary endpoint: Recurrence-free survival. Started Aug 2021; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2021-08-12_010203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-12_010203.